Showing results (191-200 of 942) with videos related to

Sort By:
Pageof 95
Atherosclerosis|July 31, 1999
Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteriesM B Steins, T Padró, C X Li, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitroA W Himmelmann, S Danhauser-Riedl, G Steinhauser, et al.
Cancer|July 1, 1993
Single-agent carboplatinum for advanced seminoma. A phase II studyH J Schmoll, A Harstrick, C Bokemeyer, et al.
The European Respiratory Journal|February 14, 2009
Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatmentM Kreuter, M Kropff, A Fischaleck, et al.
Investigational New Drugs|July 30, 1999
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusionI Rassmann, R Thödtmann, M Mross, et al.
British Journal of Haematology|February 26, 2000
Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cellsR Fenski, K Flesch, S Serve, et al.
Cancer Research|January 1, 1991
Some antagonists of platelet activating factor are cytotoxic for human malignant cell linesS Danhauser-Riedl, S B Felix, W J Houlihan, et al.
Oncology|October 17, 2002
Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trialE Oelmann, M Thomas, H Serve, et al.
Blood|June 22, 2001
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemiaR M Mesters, T Padró, R Bieker, et al.
Annals of Hematology|May 6, 2004
Transplantation strategies in AML: AMLCG dataJ Kienast, M Stelljes, B Berning, et al.
Pageof 95